Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

The use of artificial intelligence may help determine how breast cancer tumors develop resistance to certain therapies, notes Rakhshanda Rahman, MD, FRCS, FACS.

Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.

Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Investigators are assessing rhenium obisbemeda as a treatment for breast cancer harboring leptomeningeal metastases as part of the phase 1/2a ReSPECT-LM trial.